Foodconsumer.org

 
USCards.com Bookmark Us
All Food, Diet and Health News 
 
 Misc. News
 Must-Read News
 Letter to Editor
 Featured Products
 Recalls & Alerts
 Consumer Affair
 Non-food Things
 Health Tips
 Interesting Sites
 
 Diet & Health
 Heart & Blood
 Cancer
 Body Weight
 Children & Women
 General Health
 Nutrition
 
 Food & Health
 Food Chemicals
 Biological Agents
 Cooking & Packing
 Technologies
 Agri. & Environ.
 Laws & Politics
 
 General Health
 Drug News
 Diseases
 Mental Health
 Infectious Disease
 Environment
 Lifestyle
 Government
 Other News
 
 Food Consumer
 FC News & Others
Search





Search Foodconsumer & Others


Add to Google
Add to My Yahoo
Newsfeed

foodconsumer.org news feed
Su bmit news[release]



More than 100 credit cards available at uscards.com from uscards.com, you can pick more than 100 credit cards


General Health : Drug News Last Updated: Apr 20, 2011 - 9:38:09 AM


How Did Dangerous Risperdal Become a Best Selling Drug?
By Martha Rosenberg
Jan 18, 2009 - 12:53:33 PM

E.mail t.his a.rticle
 P.rinter f.riendly p.age
Get n.ewsletter
 
   
The email did not beat around the bush.

"The rationale of this center," wrote Christine Cote, VP of Janssen's Medical Affairs about the planned MGH-Johnson & Johnson Center for the Study of Pediatric Psychopathology at Massachusetts General Hospital, "is to generate and disseminate data supporting the use of risperidone in this patient population."

Okaaaaay.

But even as postmortems are performed on the unholy alliance between Massachusetts General Hospital and Johnson & Johnson which surfaced last year, the drug giant is at it again.

In January, Janssen Pharmaceutica N.V., a unit of Johnson & Johnson, announced it was funding a research venture at Vanderbilt University in Nashville, TN to discover "novel drugs for the treatment of schizophrenia," to be led by Jeffrey Conn, former head of Merck's department of neuroscience.

Of course you can't blame J&J for seeking new academic stomping   grounds. Its chief academic cheerleader, Harvard child psychiatrist Joseph "Risperdal" Biederman, who headed its center at Mass Gen, has been benched for apparent psychopathology-for-pay schemes under which he increased the diagnosis of pediatric bipolar disorder fortyfold.

Janssen is being sued by Texas, New Mexico and other states for hiding Risperdal dangers, marketing it for unapproved uses, ghostwriting, misleading doctors, falsifying science, kickback schemes and wholesale Medicaid fraud.

And-- Risperdal's US patent expired in 2008!

Risperdal ( risperidone), an atypical antipsychotic, may have contributed to the deaths of 31 children since its 1993 approval according to the New York Times--including 11 treated for unapproved uses; it may have squandered millions of tax dollars, but it is a branding success story.

How else do you explain a drug for schizophrenia--1 percent of the population--bipolar disorder-- 2.5 percent-- and autism-related irritability in children 5-16--less than 1 percent of kids--becoming the seventh best selling med in the world in 2007?

Of course some of Risperdal's success came from the award-winning "Living Nightmares" campaign by London-based ad agency Junction 11 which used Welsh artist Mark Moran's evocative oil paintings Dog-Woman, Witches, Rotting Flesh and Boiling Rain--get it?-- based on case histories to "own the relapse/prevention space" as art director John Timney put it.

And don't forget the Prescribe Early campaign by ad agency Torre Lazur McCann which used a macabre abandoned wallet, teddy bear and keys on a barren street to "to reposition a drug that was being used too late to achieve its maximum benefits,"--look what happens when you wait!--according to Pharma Times magazine.

Nor did the continuing   medical education courses like   "Individualizing ADHD Pharmacotherapy with Disruptive Behavioral Disorders" taught by the J&J funded Robert L. Findling and referring to Risperdol/risperdone 13 times hurt. Credit was available until 2009.

But most of Risperdal's success comes from the unsung doctors--you know who you are--who extolled the drug for unapproved use in pediatric bipolar disorder, ADHD, depression, " agitated, expansive, grandiose" "psychopathologies" [per Biederman], Alzheimer's, jealousy, "oppositional" disorder, borderline states, assorted neurological diseases, sleep and mood disorders and whatever else would stick to the wall.

Like the doctors who upheld the "long-term safety and effectiveness of risperidone for severe disruptive behaviors in children," on the basis of a one-year study in The Journal of the American Academy of Child and Adolescent Psychiatry in 2005. Hello?

How else could a drug known to cause diabetes, obesity, breasts in men, lactation in women and the very tardive dyskinesia it was supposed to prevent be a first choice drug in state formularies and on Medicaid protocols? Given to children?

How did it become a preferred nursing home treatment--Taylor Park Nursing and Rehabilitation Center resident Bruce Bowman in Rhinelander, WI died last June after being put on Risperdal reports the Milwaukee Journal Sentinel--despite a warning label that says it increases death in elderly patients with dementia-related psychosis?

Nor did the FDA's why-hold-up-a-drug-just-because-it's-dangerous attitude hurt. In 2007, it approved Risperdal for adolescents 13-17 with schizophrenia and children and adolescents 10-17 with "short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder" on the basis of two six to eight week studies. Barely long enough to need validated parking.

In fact the FDA was surprised when a panel of drug experts called together in November unanimously rejected its routine safety monitoring for Risperdal and related drugs for children out of hand.

"I’m a little puzzled about the statement that the label is inadequate," said Dr. Thomas Laughren, director of the agency's division of psychiatry products according to the New York Times. "I’m anxious to hear what more we can do."

How about not approving a drug in the first place?





© 2004-2008 by foodconsumer.org unless otherwise specified

Top of Page




Google
 
Web foodconsumer.org

Search Consumer-friendly Health Sites












We have moved to Food Consumer . Org



disclaimer | advertising | jobs | privacy | about us | newsletter | Submit news/articles
link partners: | Buy Viagra | MarketAmerica.com |
Buy a home | Auto Insurance | Mortgage refinancing | DaytonaCPA.com | Take Your Blog to a Higher Level
© Copyright 2004 - 2008 foodconsumer.org All rights reserved

Disclaimer: What's published on this website should be considered opinions of respective writers only and foodconsumer.org which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only. The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals. Foodconsumer.org encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.